

# **Gastroesophageal Cancer Reference Handout**

## Esophageal Cancer

**Squamous Cell**  
Upper/Middle Esophagus

**Adenocarcinoma**  
Lower Esophagus/GEJ

## Gastroesophageal Cancer

### GEJ Tumors: Siewert Scale

- I = 1-5 cm above GEJ → tx as esophageal
- II = 1 above/2 cm below GEJ → tx as esophageal
- III = 2-5 cm below GEJ → tx as gastric

### Gastroesophageal Staging

#### T

- T1 = lamina propria, muscularis mucosa, submucosa
- T2 = muscularis propria
- T3 = subserosa/adventitia
- T4 = serosa
  - T4a = pericardia, pleura
  - T4b = aorta, trachea, vertebrae

#### N (need 15 LN for staging)

- N1 = 1-2 LN
- N2 = 3-6 LN
- N3 = 7+ LN

## Esophageal Cancer Tx Early Stage

### Low-Grade Dysplasia

**Anti-reflux tx**  
Repeat EGD 6-12 months

### High-Grade Dysplasia

**Endoscopic Mucosal Resection (EMR)**  
**Radiofrequency Ablation (RFA)**

### Stage I Esophageal

**Esophagectomy**  
T1-T2 (< 2 cm)  
N0  
Well-differentiated

### Locally Advanced, Resectable

**T2+ or N+**

**1. Surgery + ChemoRT**  
Carboplatin/Paclitaxel Qweek  
RT = 50 Gy x 5-6 weeks

**2. Adjuvant nivolumab**

### Locally Advanced, Unresectable

**T4b (≤ T4a are resectable)**  
**Cervical esophageal**  
**ChemoRT**

## Gastric Cancer Tx Early Stage

### Stage I Gastric

**T1N0 = Surgery**  
EMR if < 2 cm

**Surgery:**  
Non-Cardiac:  
sub-total or total gastrectomy  
Cardiac:  
gastrectomy  
+/- partial esophagectomy

#### LND:

D2 = celiac axis LND = SOC

### Locally Advanced, Resectable

**T2+ or N+**

**Surgery + Perioperative Chemo**

**FLOT = (F) 5FU**  
(L) Leucovorin  
(O) Oxaliplatin  
(T) Docetaxel

### Locally Advanced, Resectable

**T2+ or N+, NO periop chemo**  
D2 → chemo  
D1/R2 → chemoRT

**Chemo or ChemoRT**

### Locally Advanced, Unresectable

**No Surgery**

**Chemo or ChemoRT**

## Esophageal Cancer

**Squamous Cell**  
Upper/Middle Esophagus

**Adenocarcinoma**  
Lower Esophagus/GEJ

## Gastroesophageal Cancer

### GEJ Tumors: Siewert Scale

- I = 1-5 cm above GEJ → tx as esophageal
- II = 1 above/2 cm below GEJ → tx as esophageal
- III = 2-5 cm below GEJ → tx as gastric

### Gastroesophageal Staging

#### T

- T1 = lamina propria, muscularis mucosa, submucosa
- T2 = muscularis propria
- T3 = subserosa/adventitia
- T4 = serosa
  - T4a = pericardia, pleura
  - T4b = aorta, trachea, vertebrae

#### N (need 15 LN for staging)

- N1 = 1-2 LN
- N2 = 3-6 LN
- N3 = 7+ LN

## Esophageal Cancer Tx Metastatic

### Front-Line

**FOLFOX** =  
(FOL) 5FU + Leucovorin  
(OX) Oxaliplatin

**CAPOX** =  
(CAP) Capecitabine  
(OX) Oxaliplatin

**HER2+:** ADD trastuzumab  
**HER2-:** ADD pembro or nivo

### Second-Line/POD

#### Adenocarcinoma/GEJ

Ramucirumab +/- Paclitaxel  
Enhertu (HER2+)  
Docetaxel or Paclitaxel  
Irinotecan  
Pembrolizumab (3<sup>rd</sup>, CPS >1%)  
Trifluridine-Tipiracil/Lonsurf (3<sup>rd</sup>)

#### Squamous Cell

Pembrolizumab (CPS >10 %)  
Nivolumab  
Docetaxel or Paclitaxel  
Irinotecan

### Targeted Therapies

**HER2+**  
Trastuzumab  
Enhertu

**MMR/MSI-H or CPS/PDL1**  
Pembrolizumab  
Nivolumab

**NTRK**  
Entrectinib  
Larotrectinib

## Gastric Cancer Tx Metastatic

### Front-Line

**FOLFOX** =  
(FOL) 5FU + Leucovorin  
(OX) Oxaliplatin

**CAPOX** =  
(CAP) Capecitabine  
(OX) Oxaliplatin

**HER2+:** ADD trastuzumab +/- pembrolizumab  
**HER2-:** ADD nivolumab

### Second-Line/POD

Ramucirumab +/- Paclitaxel  
Enhertu (HER2+)  
Docetaxel or Paclitaxel  
Irinotecan  
Trifluridine-Tipiracil/Lonsurf (3<sup>rd</sup>)  
Pembrolizumab (3<sup>rd</sup>, CPS >1%)

### Targeted Therapies

**HER2+**  
Trastuzumab  
Enhertu

**MMR/MSI-H or CPS/PDL1**  
Pembrolizumab  
Ipilimumab/Nivolumab

**NTRK**  
Entrectinib  
Larotrectinib